# West African Emerging Infectious Disease Research Center (WA-EIDRC)

> **NIH NIH U01** · SCRIPPS RESEARCH INSTITUTE, THE · 2022 · $1,848,854

## Abstract

PROJECT SUMMARY
With the increasing use of oral antiviral treatments for acute SARS-CoV-2 infection, there
have been multiple reports of symptom and viral load rebound after the prescribed
treatment course. The most prescribed oral antiviral is Paxlovid, and while it has become a
component of test-to-treat programs, there are no incidence or prevalence numbers on
Paxlovid (symptomatologic and/or virologic) rebound after the five-day treatment course.
Further, the connection between symptoms, viral load rebound, and immune correlates is
unknown as well. This is of utmost urgence from a public health standpoint, given the
possibility of the individual remaining infectious despite Paxlovid treatment and concerns
about the potential development of drug resistance. Therefore, with additional funding we
propose to study the incidence, prevalence, symptomatology, virus evolution, and immune
correlates of COVID-19 cases who rebound after completion of Paxlovid treatment.

## Key facts

- **NIH application ID:** 10653441
- **Project number:** 3U01AI151812-03S2
- **Recipient organization:** SCRIPPS RESEARCH INSTITUTE, THE
- **Principal Investigator:** Kristian Graugaard Andersen
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,848,854
- **Award type:** 3
- **Project period:** 2022-09-09 → 2024-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10653441

## Citation

> US National Institutes of Health, RePORTER application 10653441, West African Emerging Infectious Disease Research Center (WA-EIDRC) (3U01AI151812-03S2). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10653441. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*